tetano
Editor, Senior Moderator
Biomed Pharmacother
. 2024 May 27:176:116781.
doi: 10.1016/j.biopha.2024.116781. Online ahead of print. H1N1 nanobody development and therapeutic efficacy verification in H1N1-challenged mice
Jaehyun Hwang[SUP] 1 [/SUP], In-Young Jang[SUP] 2 [/SUP], Eunseo Bae[SUP] 1 [/SUP], Jaeseok Choi[SUP] 1 [/SUP], Jeong Hwan Kim[SUP] 2 [/SUP], Sang Beum Lee[SUP] 2 [/SUP], Jong Hyun Kim[SUP] 2 [/SUP], Jae Pil Lee[SUP] 2 [/SUP], Ho Young Jang[SUP] 2 [/SUP], Hyoung Tae Kim[SUP] 2 [/SUP], Jong-Woo Lim[SUP] 3 [/SUP], Minjoo Yeom[SUP] 3 [/SUP], Eunhee Jang[SUP] 4 [/SUP], Seong-Eun Kim[SUP] 4 [/SUP], Hyoung Hwa Jeong[SUP] 4 [/SUP], Jung Woo Kim[SUP] 4 [/SUP], Seung-Yong Seong[SUP] 5 [/SUP], Daesub Song[SUP] 6 [/SUP], Woonsung Na[SUP] 7 [/SUP]
Affiliations
Influenza A virus causes numerous deaths and infections worldwide annually. Therefore, we have considered nanobodies as a potential treatment for patients with severe cases of influenza. We developed a nanobody that was expected to have protective efficacy against the A/California/04/2009 (CA/04; pandemic 2009 flu strain) and evaluated its therapeutic efficacy against CA/04 in mice experiments. This nanobody was derived from the immunization of the alpaca, and the inactivated CA/04 virus was used as an immunogen. We successfully generated a nanobody library through bio-panning, phage ELISA, and Bio-layer interferometry. Moreover, we confirmed that administering nanobodies after lethal doses of CA/04 reduced viral replication in the lungs and influenza-induced clinical signs in mice. These research findings will help to develop nanobodies as viral therapeutics for CA/04 and other infectious viruses.
Keywords: Influenza; Mice experiment; Nanobody; Pandemic 2009 flu; Viral therapeutic.
. 2024 May 27:176:116781.
doi: 10.1016/j.biopha.2024.116781. Online ahead of print. H1N1 nanobody development and therapeutic efficacy verification in H1N1-challenged mice
Jaehyun Hwang[SUP] 1 [/SUP], In-Young Jang[SUP] 2 [/SUP], Eunseo Bae[SUP] 1 [/SUP], Jaeseok Choi[SUP] 1 [/SUP], Jeong Hwan Kim[SUP] 2 [/SUP], Sang Beum Lee[SUP] 2 [/SUP], Jong Hyun Kim[SUP] 2 [/SUP], Jae Pil Lee[SUP] 2 [/SUP], Ho Young Jang[SUP] 2 [/SUP], Hyoung Tae Kim[SUP] 2 [/SUP], Jong-Woo Lim[SUP] 3 [/SUP], Minjoo Yeom[SUP] 3 [/SUP], Eunhee Jang[SUP] 4 [/SUP], Seong-Eun Kim[SUP] 4 [/SUP], Hyoung Hwa Jeong[SUP] 4 [/SUP], Jung Woo Kim[SUP] 4 [/SUP], Seung-Yong Seong[SUP] 5 [/SUP], Daesub Song[SUP] 6 [/SUP], Woonsung Na[SUP] 7 [/SUP]
Affiliations
- PMID: 38805966
- DOI: 10.1016/j.biopha.2024.116781
Influenza A virus causes numerous deaths and infections worldwide annually. Therefore, we have considered nanobodies as a potential treatment for patients with severe cases of influenza. We developed a nanobody that was expected to have protective efficacy against the A/California/04/2009 (CA/04; pandemic 2009 flu strain) and evaluated its therapeutic efficacy against CA/04 in mice experiments. This nanobody was derived from the immunization of the alpaca, and the inactivated CA/04 virus was used as an immunogen. We successfully generated a nanobody library through bio-panning, phage ELISA, and Bio-layer interferometry. Moreover, we confirmed that administering nanobodies after lethal doses of CA/04 reduced viral replication in the lungs and influenza-induced clinical signs in mice. These research findings will help to develop nanobodies as viral therapeutics for CA/04 and other infectious viruses.
Keywords: Influenza; Mice experiment; Nanobody; Pandemic 2009 flu; Viral therapeutic.